title: ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.
abstract: BACKGROUND
  The assay for ADAMTS13 activity helps clinicians to confirm the clinical diagnosis of idiopathic thrombotic thrombocytopenic purpura. The clinical value of testing for the antigen level of ADAMTS13 protein is, however, less clear.
  
  
  METHODS
  In this study, both ADAMTS13 antigen and activity levels were measured in 835 sequential samples from 40 consecutive patients who were followed for an average of 29 months throughout the course of acute episode plasma exchange treatment and clinical remission.
  
  
  RESULTS
  During acute episodes, ADAMTS13 activity was severely deficient while ADAMTS13 antigen levels were more variable, ranging from severely deficient to as high as within the reference range. A severe depletion of ADAMTS13 antigen level during acute disease was, however, statistically associated with disease mortality (P=0.0322). For patients who achieved initial clinical responses, ADAMTS13 antigen levels appeared to be restored faster than ADAMTS13 activity to the normal range. Further analysis demonstrated that the ADAMTS13 antigen level at the time of initial clinical recovery was significantly higher in the patients who subsequently achieved a sustained clinical remission than in the group who soon after had an exacerbation (P=0.0187).
  
  
  CONCLUSIONS
  Our data suggest that evaluation of ADAMTS13 antigen levels during the course of therapy and follow-up may offer additional useful information for the management of patients with thrombotic thrombocytopenic purpura.
authors: Department of Pathology, College of Medicine, Ohio State University, Columbus, OH 43210, USA.
authors: Shangbin
authors: S
authors: Yang
authors: Ming
authors: M
authors: Jin
authors: Shili
authors: S
authors: Lin
authors: Spero
authors: S
authors: Cataland
authors: Haifeng
authors: H
authors: Wu
references: J Thromb Haemost. 2004 Mar;2(3):485-91
references: 15009467
references: Am J Hematol. 2008 Dec;83(12):911-5
references: 18821711
references: N Engl J Med. 1998 Nov 26;339(22):1585-94
references: 9828246
references: J Clin Apher. 1998;13(1):16-9
references: 9590492
references: Br J Haematol. 2007 Nov;139(3):486-93
references: 17910638
references: Blood. 2005 Sep 15;106(6):1932-7
references: 15933059
references: J Thromb Haemost. 2006 Dec;4(12):2733-7
references: 16972936
references: J Clin Invest. 2005 Oct;115(10):2752-61
references: 16200209
references: Nature. 2001 Oct 4;413(6855):488-94
references: 11586351
references: Br J Haematol. 2008 May;141(5):651-8
references: 18397340
references: Thromb Haemost. 2004 Apr;91(4):806-11
references: 15045144
references: Thromb Haemost. 2006 Apr;95(4):749-50
references: 16601853
references: Annu Rev Biochem. 1998;67:395-424
references: 9759493
references: Br J Haematol. 2006 Jan;132(2):204-9
references: 16398654
references: J Thromb Haemost. 2006 Mar;4(3):698-9
references: 16460463
references: Thromb Haemost. 2006 Feb;95(2):212-20
references: 16493480
references: Hematology. 2005;10 Suppl 1:47-8
references: 16188633
references: N Engl J Med. 2006 May 4;354(18):1927-35
references: 16672704
references: Blood. 2005 Jul 1;106(1):11-7
references: 15774620
references: Br J Haematol. 2005 Apr;129(1):93-100
references: 15801961
references: Hematology Am Soc Hematol Educ Program. 2006;:415-20
references: 17124092
references: J Thromb Haemost. 2006 Feb;4(2):333-8
references: 16420561
references: Am J Hematol. 1997 Feb;54(2):102-7
references: 9034283
references: J Thromb Haemost. 2006 Aug;4(8):1707-17
references: 16879212
references: N Engl J Med. 1998 Nov 26;339(22):1578-84
references: 9828245
references: Transfusion. 2007 Jan;47(1):107-14
references: 17207238